- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md., Nov. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.
Conference Details: | |||||
Fireside Chat | |||||
Date: | Wednesday, November 15, 2023 | ||||
Time: | 9:00 – 9:25 a.m. Greenwich Mean Time (GMT) | ||||
Location: | London | ||||
Moderator: | Roger Song, M.D., CFA, Equity Analyst | ||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Wednesday, November 15, 2023 | ||||
Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 45 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
[email protected]
Media
Ali Chartan
240-720-7804
[email protected]
SOURCE NOVAVAX, INC
